logo
Plus   Neg
Share
Email

Musk Says Tesla Has "good Chance" To Reach New Record Deliveries This Quarter

Tesla Inc. (TSLA) CEO Elon Musk says the luxury electric car maker has a "good chance" to reach record number of deliveries this quarter.

According to an email sent by Musk to employees, Tesla is on pace for a new record quarter for deliveries, which will beat the previous record achieved at the end of last year. In the fourth quarter of 2018, Tesla delivered a record of 90,700 cars, its best quarter in its history, which helped it report its second quarterly profit in a row.

"As of yesterday, we had over 50,000 net new orders for this quarter. Based on current trends, we have a good chance of exceeding the record 90,700 deliveries of Q4 last year and making this the highest deliveries/sales quarter in Tesla history!" Musk said in the email.

"In order to achieve this, we need sustained output of 1,000 Model 3's per day. Almost all parts of the Model 3 production system have exceeded 1,000 units on multiple days (congratulations!!) and we've averaged about 900/day this week, so we're only about 10% away from 7,000/week."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
JPMorgan Chase CEO Jamie Dimon said it expects the bank's earnings to be "down meaningfully" in 2020 due to the disruptions created by coronavirus pandemic. He also noted that the U.S. was not adequately prepared for the pandemic. In his annual letter to the company's shareholders, Dimon said that the bank's board may consider suspending the dividend in an extremely adverse scenario. The U.S. Food and Drug Administration launched a national effort to facilitate the development of blood-related therapies to combat the ongoing coronavirus (COVID-19) pandemic. The FDA is focused on two investigational therapies derived from human blood called convalescent plasma and hyperimmune globulin, which are antibody-rich blood products made from blood donated by people who have recovered. Gilead Sciences Inc. said it is donating its existing supply of 1.5 million individual doses of remdesivir, its investigational medicine for coronavirus or Covid-19. The drug, which is yet to get regulatory approval, is available for compassionate use, expanded access and clinical trials to treat patients with the most severe symptoms of COVID-19.
Follow RTT
>